Table 1. IL-34 mRNA expression in a panel of human breast cancer cell lines.

Cell line	Cell type	ER*	PR*	HER2*	Vimentin*	N-cad*	IL-34 log2	Subtype*
HMEC	normal						3,16
Hs 578Bst	normal						−3,80
MCF 10A	F						−3,08
MCF 10F	F						0,00
MCF7	tumor	+	+	−	−	−	−2,62	Luminal A
ZR-75-1	tumor	+	+	−	−		−0,82	Luminal A
T-47D	tumor	+	+	−	−		−2,28	Luminal A
CAMA-1	tumor	+	+	−	−		−0,76	Luminal A
BT-474	tumor	+	+	+	−		−3,81	Luminal B
SK-BR-3	tumor	−	−	+	−	−	−1,62	HER2
AU565	tumor	−	−	+			−1,75	HER2
MDA-MB-453	tumor	−	−	+	−	−	n.a.	HER2
MDA-MB-231	tumor	−	−	−	+	−	−0,76	Basal
MDA-MB-468	tumor	−	−	−	−		1,47	Basal
CAL-51	tumor	−		−			−1,78	Basal
HCC1143	tumor			−			3,74	Basal
HCC1937	tumor	−	−	−			2,42	Basal
Hs 578T	tumor	−	−	−	+	+	−0,22	Basal

F, fibrocystic disease; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor-2; N-cad, N-cadherin IL-34, interleukin-34; normal, untransformed human mammary epithelial cells; n.a., not applicable.

^*Determined from references [65–70].